Platelet and Red Blood Cell Volume Indices as Inflammatory Biomarkers in Ankylosing Spondylitis
NCT05997108 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70
Last updated 2023-08-18
Summary
this study aims to determine the relatioships among the NLR ,PLR ,MLR ,red cell volume and platelet volume indices levels as biomarkers in ankylosing spondylitis.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
CBC
Platelet and red blood cell volume indices
Sponsors & Collaborators
-
Sohag University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-08-01
- Primary Completion
- 2024-02-01
- Completion
- 2024-02-01
Countries
- Egypt
Study Locations
More Related Trials
-
Assessment of Hematologic Indices in Juvenile Lupus Erythematosus Patients:Correlation With Disease Activity and Chronic Organ Damage in These Patients
NCT06718283 ·Status: RECRUITING
-
Unmet Needs of Axial Spondyloarthrits in Egyptian Patients
NCT05517031 ·Status: UNKNOWN
-
Hematological Manifestations in Systemic Lupus Erythematosus Patients
NCT06936007 ·Status: COMPLETED
-
Role of Musculoskeletal Ultrasound for Early Detection of Synovitis in SLE Patient and Its Correlation With Disease Activity and Neutrophil-to-C3 Ratio.
NCT07067606 ·Status: NOT_YET_RECRUITING
-
Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus
NCT03179046 ·Status: COMPLETED
-
IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage
NCT05045417 ·Status: UNKNOWN
-
Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients
NCT01470183 ·Status: COMPLETED
-
Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort
NCT04534647 ·Status: UNKNOWN
-
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
NCT01541670 ·Status: TERMINATED ·Phase: PHASE1
-
Autotaxin as Abiomarker in Systemic Lupus Erythematosus Patients
NCT06063668 ·Status: NOT_YET_RECRUITING
-
The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear
NCT02435368 ·Status: UNKNOWN
-
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
NCT02034344 ·Status: COMPLETED
-
A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis
NCT04924296 ·Status: UNKNOWN ·Phase: PHASE2
-
Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus
NCT07149402 ·Status: NOT_YET_RECRUITING
-
Rheumatology Patient Registry and Biorepository
NCT04402086 ·Status: RECRUITING
-
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity
NCT06610409 ·Status: NOT_YET_RECRUITING
-
Application of MRI for Musculoskeletal Involvement in SLE
NCT04035265 ·Status: UNKNOWN ·Phase: NA
-
Study of M5049 in CLE and SLE Participants
NCT04647708 ·Status: COMPLETED ·Phase: PHASE1
-
Ankylosing Spondylitis and Antiphospholipid Antibodies
NCT02809300 ·Status: UNKNOWN ·Phase: NA
-
Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients
NCT07017868 ·Status: RECRUITING
-
Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis
NCT02453997 ·Status: COMPLETED
-
the Association Between Metabolic Syndrome and Its Components With Lupus Nephritis in Systemic Lupus Erythematosus Patients
NCT05964751 ·Status: UNKNOWN
-
S100A8 in Serum and Urine as a New Biomarker in Lupus Nephritis
NCT06872138 ·Status: COMPLETED
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
NCT05440422 ·Status: RECRUITING ·Phase: PHASE2
-
Systemic Immune Inflammatory Index in Systemic Lupus Erythematosus
NCT06796569 ·Status: RECRUITING